We are live on ! Find out more
NMTR

9 Meters Biopharma
NMTR

Delisted

NMTR was delisted on the 25th of July, 2023.

Back to rankings

3 hedge funds and large institutions have $1.25M invested in 9 Meters Biopharma in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
3
Holders Change
+3
Holders Change %
–
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$55.9K
2
GAM
Gotham Asset Management
New York
+$23.2K
3
TRCT
Tower Research Capital (TRC)
New York
+$2.21K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
GAM
1
Gotham Asset Management
New York
$1.22M +$23.2K +42 New
Goldman Sachs
2
Goldman Sachs
New York
$34K +$55.9K +101 New
TRCT
3
Tower Research Capital (TRC)
New York
$1K +$2.21K +4 New

NMTR Hedge Fund Activity: Q3 2016 in Review

3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q3 2016, worth a combined $1.25M.

Buyers outnumbered sellers: 3 funds opened new NMTR positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $55.9K.

  • 3 institutional investors held 9 Meters Biopharma (NMTR) as of Q3 2016, up from 0 in Q2 2016.
  • Funds reported $1.25M of 9 Meters Biopharma stock for Q3 2016.
  • 3 funds opened new 9 Meters Biopharma positions in Q3 2016 and 0 closed out, a net change of +3 holders.
  • The largest 9 Meters Biopharma buyer in Q3 2016 was Goldman Sachs, an estimated $55.9K added.

Based on aggregated 13F filings for Q3 2016.